Buscarino, Michela
Candiolo Cancer Institute
8 papers on CoChat
Most cited papers
- Verified
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 1,889
- Verified
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 939
- Verified
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
Medico, E., Russo, M., Picco, G., Cancelliere, C., Valtorta, E., Corti, G., Buscarino, M., Isella, C., Lamba, S., Martinoglio, B., et al. (2015) · Nature Communications
Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics
Cited by 302
- Verified
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 263
- Verified
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 214
- Verified
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Migliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research
Colorectal Cancer Treatments and StudiesPI3K/AKT/mTOR signaling in cancer
Cited by 191
- Verified
Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
Molinari, F., Felicioni, L., Buscarino, M., De Dosso, S., Buttitta, F., Malatesta, S., Movilia, A., Luoni, M., Boldorini, R., Alabiso, O., et al. (2011) · Clinical Cancer Research
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 159
- Verified
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF -Mutant Colorectal Cancer
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research
Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways
Cited by 121
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free